Compositions and methods for modulating sos gene expressions
AssigneeMolecular Axiom, LLC
InventorsLishan CHEN, Bohan JIN
Life of this patent
Estimating the term…
Abstract
Described herein are compositions for modulating gene expressions. Also described herein are methods for using the compositions described herein for modulating gene expressions.
Claims40
A composition comprising an antisense oligonucleotide capable of binding to son of sevenless 1 (SOS1) or son of sevenless 2 (SOS2) mRNA, wherein the antisense oligonucleotide comprises a sequence having at least 80%, 85%, or 90% similarity to one of the following sequences:
- SEQ ID NOs:
- 405, 406, 539, 540, 671, 732, 741, 742, 797, 976, 1076, 1077, 1083, 1086, 1198, 1224, 1279, 1360, 1370, 1507, 1508, 1516, 1519, 1601, 1609, 1811, 1836, 1843, 1844, 1868, 1939, 1942, 1943, 1944, 2465, 2473, 2490, 2498, 2600, 2606, 2688, 2701, 2703, 2908, 2974, 2984, 3007, 3016, 3034, 3078, 3104, 3279.3305, 3308, 3386, 3615, 3673, 3677, 3680, 3682, 3687, 3765, 3821, 3879, 3880, 3949, 4134, 4156, 4173, 4177, 4178, 4182, 4183, 4222, 4466, 4687, 4692, 4736, 4781, 4935, 5118, 5144, 5384, 5394, 5435, 5449, 5455, 5457, 5459, 5780, 6060, 6061, 6532, 6611, 6621, 6625, 6627, 6803, 7368, 7471, 7516, 7589, 7865, 8087, 8201, 8207, 8208, 8331, 8617, 8651, or 8659.
A composition comprising an antisense oligonucleotide capable of binding to son of sevenless 1 (SOS1) or son of sevenless 2 (SOS2) mRNA, wherein the antisense oligonucleotide comprises a sequence having at least 8 consecutive nucleotides of one of the following sequences:
- SEQ ID NOs:
- 405, 406, 539, 540, 671, 732, 741, 742, 797, 976, 1076, 1077, 1083, 1086, 1198, 1224, 1279, 1360, 1370, 1507, 1508, 1516, 1519, 1601, 1609, 1811, 1836, 1843, 1844, 1868, 1939, 1942, 1943, 1944, 2465, 2473, 2490, 2498, 2600, 2606, 2688, 2701, 2703, 2908, 2974, 2984, 3007, 3016, 3034, 3078, 3104, 3279, 3305, 3308, 3386, 3615, 3673, 3677, 3680, 3682, 3687, 3765, 3821, 3879, 3880, 3949, 4134, 4156, 4173, 4177, 4178, 4182, 4183, 4222, 4466, 4687, 4692, 4736, 4781, 4935, 5118, 5144, 5384, 5394, 5435, 5449, 5455, 5457, 5459, 5780, 6060, 6061, 6532, 6611, 6621, 6625, 6627, 6803, 7368, 7471, 7516, 7589, 7865, 8087, 8201, 8207, 8208, 8331, 8617, 8651, or 8659.
A method of modulating KRAS-mediated signaling pathway in a cancer cell in need of, comprising:
- treating the cancer cell with a composition comprising antisense oligonucleotide capable of binding to son of sevenless 1 (SOS1) or son of sevenless 2 (SOS2) mRNA, thereby reducing expression of SOS1 or SOS2 protein or mRNA in the cancer cell.
Dependencies are inferred from the claim text.